Mahesh Kyasani

Evaluation of safety and immunogenicity of receptor-binding domain-based COVID-19 vaccine (Corbevax) to select the optimum formulation in open-label, multicentre, and randomised phase-1/2 and phase-2 clinical trials

Subhash Thuluva, Vikram Paradkar, Subba Reddy Gunneri et al. · EBioMedicine · 2022 · 74 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +16

Safety, tolerability and immunogenicity of Biological E’s CORBEVAX™ vaccine in children and adolescents: A prospective, randomised, double-blind, placebo controlled, phase-2/3 study

Subhash Thuluva, Vikram Paradkar, SubbaReddy Gunneri et al. · Vaccine · 2022 · 33 citations

Veterinary Medicine, Immunology, Pediatrics +15

Immunogenicity and safety of Biological E’s CORBEVAX™ vaccine compared to COVISHIELD™ (ChAdOx1 nCoV-19) vaccine studied in a phase-3, single blind, multicentre, randomized clinical trial

Subhash Thuluva, Vikram Paradkar, SubbaReddy Gunneri et al. · Human Vaccines & Immunotherapeutics · 2023 · 32 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +17

Simian Immunodeficiency Virus Vpx Is Imported into the Nucleus via Importin Alpha-Dependent and -Independent Pathways

Prabhat K. Singhal, Pankaj Kumar, Mahesh Kyasani et al. · Journal of Virology · 2005 · 18 citations

Life Sciences, Cell Biology, Molecular Biology +17

Selection of optimum formulation of RBD-based protein sub-unit covid19 vaccine (Corbevax) based on safety and immunogenicity in an open-label, randomized Phase-1 and 2 clinical studies

Subhash Thuluva, Vikram Paradkar, Kishore Turaga et al. · medRxiv · 2022 · 10 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +17